Humana Inc. HUM

Humana Inc. es una empresa de salud y bienestar. La Compañía opera a través de dos segmentos: Seguro y CenterWell. El segmento de Seguro consta de beneficios de Medicare, comercializados a individuos o directamente a través de cuentas grupales de Medicare. También incluye su contrato con los Centros de Servicios de Medicare y Medicaid (CMS) para administrar el programa de plan de medicamentos con ingresos limitados recién elegibles (LI-NET) y contratos con varios estados para proporcionar beneficios de Medicaid, demostración de elegibilidad dual y servicios de apoyo a largo plazo. El segmento de Seguro también incluye productos que consisten en seguros médicos comerciales totalmente asegurados para grupos de empleadores y salud especializada. El segmento CenterWell representa sus ofertas de servicios de atención médica agnósticos al pagador, que incluyen servicios de dispensación de farmacia, servicios de proveedores y servicios domiciliarios. Las subsidiarias de la Compañía incluyen Mid-South Home Health Agency, LLC, Premier Home Health Agency, LLC y Humana Regional Health Plan, Inc.

Con 2 acciones de HUM (USD 808,09) habrías recibido USD 5,34 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 30 sept

  Announcing the Winners of the 2026 TrustMaker Awards by OneTrust

  OneTrust announced the winners of its 2026 TrustMaker Awards at TrustWeek, recognizing organizations excelling in responsible AI governance and data use. Fiserv, Workday, Humana, and Rockwell Automation were honored for their achievements in AI governance, operational excellence, impact, and overall trust leadership respectively. OneTrust also unveiled CORIE, a new platform innovation designed to govern AI agents at enterprise scale.

  

• GlobeNewswire Inc. 25 sept

  The American Journal of Managed Care® announces Aaron L. Schwartz, M.D., Ph.D., as 2026 Emerging Leader in Managed Care Research Award recipient

  Dr. Aaron L. Schwartz, an assistant professor at the University of Pennsylvania, has been awarded the 2026 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award for his groundbreaking work on low-value care metrics and prior authorization research. His claims-based measures have been adopted by CMS for accountable care programs, and his research has influenced policy decisions at major healthcare organizations and government agencies.

  

• Zacks Investment Research 17 sept

  Can Centene Sustain Its Turnaround Amid Membership Pressure?

  Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior, driven by improved medical cost trends and better execution. The company expects Medicaid membership to decline 8%-9% in 2026, but profitability improvements in Marketplace and Medicare segments, combined with higher Medicaid rates and cost initiatives, support continued recovery. CNC reaffirmed its 2026 adjusted EPS guidance above $4.80.

  

• GlobeNewswire Inc. 16 sept

  Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

  The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.

  

• Zacks Investment Research 16 sept

  Is Invesco S&P 500 Pure Value ETF (RPV) a Strong ETF Right Now?

  The Invesco S&P 500 Pure Value ETF (RPV) is a smart beta ETF with $1.75 billion in assets that tracks the S&P 500 Pure Value Index. It has delivered 19.31% year-to-date returns and 26.47% over the past year with a 0.35% expense ratio. The fund holds 125 stocks with heavy exposure to Financials (20.4%), Healthcare, and Consumer Staples sectors. While RPV offers reasonable value-focused exposure, cheaper alternatives like Vanguard's VTV (0.03% expense ratio) and Schwab's SCHD (0.06% expense ratio) may be more cost-effective for investors.